Regarding anti‐EGFR antibody, panitumumab is effective for increasing the overall response rate (ORR) and resection rate.48, 49 However, when determining the optimal multidisciplinary treatment strategy for KRAS wild‐type liver‐limited, initially unresectable CRC, no unequivocal evidence shows that molecular targeted therapy in combination with chemotherapy is better with either anti‐VEGF antibody or anti‐EGFR antibody despite the presence of data suggesting that “liver resection rate,” “improvement of response rate,” and “pathological improvement” improve prognosis. Here, KRAS is linked to colorectal carcinoma.